Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ann Thorac Surg. 2020 Jan;109(1):270-276. doi: 10.1016/j.athoracsur.2019.07.037. Epub 2019 Aug 31.
There has been growing interest in limited resection and nonsurgical treatment for small lung cancers. We examined the pattern and rate of occult N1 nodal metastasis in patients with peripheral, small (≤2 cm), clinically node-negative non-small cell lung cancer (NSCLC).
Patients with peripheral small (≤2 cm) NSCLC with no evidence of locally advanced or metastatic disease (clinical T1a-b N0 M0, American Joint Committee on Cancer 8th Edition Cancer Staging Manual), who were deemed eligible for lobectomy or sublobar resection, were identified from preregistration eligibility screening logs for the Alliance/Cancer and Leukemia Group B 140503 trial at our institution. Pathologic outcomes were examined in all patients undergoing anatomic resection with mediastinal and hilar lymphadenectomy.
Included were 58 patients treated between November 2014 and January 2017 who met the inclusion criteria: 51 underwent lobectomy, and 7 underwent segmentectomy. Mean tumor diameter on computed tomography was 1.5 cm, and mean positron emission tomography maximal standardized uptake value was 3.9. The mean consolidation-to-tumor ratio was 0.77. Occult nodal metastases in N1 stations were found in 8 of 58 patients (14%), and most of these nodes were found in interlobar or peribronchial stations (11 or 12). An additional 2 patients (3%) had occult positive N2 nodes. Overall, the false-negative rate for clinical staging was 16%.
Occult nodal disease was frequently identified in peripheral N1 stations (11-13) in patients with small (≤2 cm) clinical N0 NSCLC. Hilar lymphadenectomy is essential for accurate staging in the management of patients with small clinical N0 NSCLC.
对于小肺癌,人们越来越关注局限性切除术和非手术治疗。我们研究了周围性、小(≤2cm)、临床淋巴结阴性非小细胞肺癌(NSCLC)患者隐匿性 N1 淋巴结转移的模式和发生率。
我们从机构内联盟/癌症和白血病组 B140503 试验的预先注册资格筛选日志中确定了符合条件的患者,这些患者患有周围性小(≤2cm)NSCLC,且无局部晚期或转移性疾病的证据(临床 T1a-bN0M0,美国癌症联合委员会第 8 版癌症分期手册),被认为有资格行肺叶切除术或亚肺叶切除术。对所有接受纵隔和肺门淋巴结清扫术的解剖性切除术患者进行病理检查。
纳入的 58 例患者于 2014 年 11 月至 2017 年 1 月符合纳入标准:51 例行肺叶切除术,7 例行节段切除术。CT 上平均肿瘤直径为 1.5cm,平均正电子发射断层扫描最大标准化摄取值为 3.9。平均实变与肿瘤比值为 0.77。58 例患者中有 8 例(14%)发现隐匿性 N1 淋巴结转移,这些淋巴结多位于叶间或支气管旁(11 或 12 区)。另外 2 例(3%)患者存在隐匿性阳性 N2 淋巴结。总体而言,临床分期的假阴性率为 16%。
在小(≤2cm)临床 N0 NSCLC 患者中,常可在周围性 N1(11-13)区发现隐匿性淋巴结疾病。在小临床 N0 NSCLC 患者的管理中,肺门淋巴结清扫术对于准确分期至关重要。